{"id":"v212","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL4287451","moleculeType":"Unknown","molecularWeight":"3657.24"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, V212 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"V212 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:52.845Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06975319","phase":"EARLY_PHASE1","title":"Phase I Study With V-212 Vaccinations in Healthy Adult Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Virometix","startDate":"2025-01-29","conditions":"Healthy, Immunisation Against Streptococcus Pneumoniae","enrollment":60},{"nctId":"NCT00696709","phase":"PHASE1","title":"A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-12","conditions":"Herpes Zoster","enrollment":290},{"nctId":"NCT01254630","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-06-24","conditions":"Herpes Zoster","enrollment":5305},{"nctId":"NCT01229267","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-11-30","conditions":"Herpes Zoster","enrollment":1257},{"nctId":"NCT00535236","phase":"PHASE1","title":"A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-11-02","conditions":"Herpes Zoster, Herpes Zoster-related Complications","enrollment":341},{"nctId":"NCT01460719","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-24","conditions":"Herpes Zoster","enrollment":80},{"nctId":"NCT01527383","phase":"PHASE2","title":"A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-21","conditions":"Herpes Zoster","enrollment":354},{"nctId":"NCT00886613","phase":"PHASE1","title":"A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Herpes Zoster","enrollment":120},{"nctId":"NCT02180295","phase":"PHASE3","title":"A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-07","conditions":"Herpes Zoster","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inactivated Varicella-Zoster (VZV) vaccine"],"phase":"phase_3","status":"active","brandName":"V212","genericName":"V212","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"V212 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":5},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}